Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
5.61B
Market cap5.61B
Price-Earnings ratio
145.86
Price-Earnings ratio145.86
Dividend yield
Dividend yield
Average volume
1.32M
Average volume1.32M
High today
$52.48
High today$52.48
Low today
$50.32
Low today$50.32
Open price
$51.00
Open price$51.00
Volume
871.73K
Volume871.73K
52 Week high
$91.00
52 Week high$91.00
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $52.28. The company's market cap stands at 5.61B, with a P/E ratio of 145.86.

As of 2026-05-09, Corcept Therapeutics(CORT) stock has fluctuated between $50.32 and $52.48. The current price stands at $52.28, placing the stock +3.9% above today's low and -0.4% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 871.73K, against a daily average of 1.32M.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $91.00 at its peak.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $91.00 at its peak.

CORT News

Simply Wall St 31m
Corcept’s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook

Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS. Patients receiving 300 mg daily experienced an 87%...

Corcept’s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook
TipRanks 5d
Corcept Therapeutics Signals Big Growth After Key Wins

Corcept Therapeutics ((CORT)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data an...

TipRanks 5d
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $75 from $60 and keeps a Buy rating on the shares. The firm says Lifyorli and K...

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.